Next Article in Journal
Ethyl 12-Sulfamoyl-abieta-8,11,13-trien-18-oate
Next Article in Special Issue
Triethylammonium 2-(3-Hydroxy-2-oxoindolin-3-yl)-5,5-dimethyl-3-oxocyclohex-1-en-1-olate
Previous Article in Journal
New Preparation of Ferrocene Carboxylic Acid Benzotriazol-1-yl Ester
Previous Article in Special Issue
(Z)-3-(Dicyanomethylene)-4-((5-fluoro-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium-2-yl) methylene)-2-(((E)-5-fluoro-3,3-dimethyl-1-(3-phenylpropyl)indolin-2-ylidene)methyl) cyclobut-1-en-1-olate
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

4-Benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione

by
Ekaterina E. Khramtsova
,
Maksim V. Dmitriev
and
Andrey N. Maslivets
*
Department of Chemistry, Perm State University, ul. Bukireva, 15, 614990 Perm, Russia
*
Author to whom correspondence should be addressed.
Molbank 2023, 2023(1), M1583; https://doi.org/10.3390/M1583
Submission received: 28 December 2022 / Revised: 9 January 2023 / Accepted: 6 February 2023 / Published: 8 February 2023
(This article belongs to the Collection Heterocycle Reactions)

Abstract

:
The reaction of 3-benzoylpyrrolo[2,1-c][1,4]benzoxazin-1,2,4-trione with N-(4-bromophenyl)-1-(4-methoxyphenyl)methanimine under thermolytical conditions afforded 4-benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione in a good yield. The reaction proceeded via in situ generation of a reactive intermediate, acyl(imidoyl)ketene. The compound was fully characterized.

1. Introduction

Pyrimidino[4,3-c][1,4]benzoxazines are oxygen-nitrogen heterocycles interesting for medical applications. For example, potential pharmaceutical substances, bearing pyrimidino[4,3-c][1,4]benzoxazine core, were developed for treatment of cancer [1], tumors [2,3], cardiovascular disorders [1] and neurological disorders [1] (Figure 1).
As a continuation of our study on the syntheses of fused heterocycles A or B via reactions of acyl(imidoyl)ketenes C, generated by the thermolysis of [e]-fused 1H-pyrrole-2,3-diones D [4] (Scheme 1), we synthesized a novel representative of 4-aroyl-1,2-diaryl-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-diones (type B heterocycles on the Scheme 1) [5]-4-benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione 1 [6], by the reaction of 3-benzoylpyrrolo[2,1-c][1,4]benzoxazin-1,2,4-trione 2 with N-(4-bromophenyl)-1-(4-methoxyphenyl)methanimine 3 under thermolysis conditions.

2. Results and Discussion

The title compound 1 was synthesized in several steps (Scheme 2). Initially, methyl benzoylpyruvate 4 was obtained by the Claisen condensation of acetophenone and diethyl oxalate [7]. Next, the reaction of compound 4 and o-aminophenol afforded benzoxazine-2-one 5 [7]. After that, acylation of compound 5 by oxalyl chloride resulted in [e]-fused 1H-pyrrole-2,3-dione 2 [8]. Finally, thermolysis of compound 2 in the presence of Schiff base 3 gave the target compound 1 in a good yield [6]. The final transformation proceeded one-pot through two steps. Firstly, pyrrolobenzoxazinetrione 2 underwent thermal decomposition to form in situ highly reactive acyl(imidoyl)ketene C. Secondly, ketene C was involved in a [4+2] cycloaddition reaction with Schiff base 3 to afford the target compound 1.
Structure of compound 1 was unambiguously confirmed by the single crystal X-ray analysis (CCDC 2047333, CCDC Refcode = FADPUZ) [6].
It should also be mentioned that compound 1 shows fluorescent properties in solid state (Figure 2) and in a solution.

3. Materials and Methods

3.1. General Information

1H and 13C NMR spectra (Supplementary Materials) were acquired on a Bruker Avance III 400 HD spectrometer (Fällanden, Switzerland) (at 400 and 100 MHz, respectively) in DMSO-d6 using the solvent residual signal (in 1H NMR, 2.50 for DMSO-d6; in 13C NMR, 39.51 for DMSO-d6) as an internal standard. IR spectrum was recorded on an FSM-1201 spectrometer (LOMO, St Petersburg, Russia) from a mull in mineral oil. The melting point was measured on a Khimlabpribor PTP apparatus (USSR). Elemental analysis was carried out on a Vario MICRO Cube analyzer (Langenselbold, Germany). Solid state fluorescence of compound 1 was photographed with Xiaomi Redmi 9A 32 Gb main camera (13 MP) (Beijing, China) in the light of a TLC viewing cabinet Petrolaser TLC-254/365 Thin Layer Chromatography Dark Room (Petrolaser, St Petersburg, Russia). The single crystal X-ray analysis of compound 1 was performed on an Xcalibur Ruby diffractometer (Agilent Technologies, Cheadle, UK). The empirical absorption correction was introduced by multi-scan method using SCALE3 ABSPACK algorithm [9]. Using WinGX [10], the structure was solved with the SHELXS [11] program and refined by the full-matrix least-squares minimization in the anisotropic approximation for all non-hydrogen atoms with the SHELXL [12] program. The hydrogen atoms were positioned geometrically and refined using a riding model. Thin-layer chromatography (TLC) was performed on Silufol (Czechoslovakia) plates using EtOAc/benzene, 1:5 v/v, benzene, EtOAc as eluents. CO was indicated by gas detector tubes Gazoopredelitel GH-4 (specifications 12.43.20-76, USSR). The starting compounds 25 were obtained according to the reported procedures [7,8,13] from commercially available reagents. All procedures with compound 2 were performed in an oven-dried glassware. Benzene and pseudocumene for procedures with compound 2 were distilled over Na before the use. All other solvents and reagents were purchased from commercial vendors and used as received.

3.2. 4-Benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione 1

A suspension of 1 g (3.1 mmol) of 3-benzoylpyrrolo[2,1-c][1,4]benzoxazin-1,2,4-trione 2 and 1 g (3.4 mmol) of N-(4-bromophenyl)-1-(4-methoxyphenyl)methanimine 3 in 50 mL of anhydrous pseudocumene was refluxed for 15 min (until evolution of CO stopped). Next, the reaction mixture was cooled to room temperature. The formed precipitate was filtered off and recrystallized from toluene to yield the title compound 1. Yield: 1.19 g (66%); yellow solid; mp 233–236 °C (decomp.). 1H NMR (DMSO-d6, 400 MHz): δ = 8.04–8.00 (m, 1 H), 7.80–7.52 (m, 5 H), 7.42–7.29 (m, 7 H), 7.24–7.17 (m, 3 H), 7.06–7.00 (m, 2 H), 3.79 (s, 3 H) ppm. 13C NMR (DMSO-d6, 100 MHz): δ = 55.2, 70.8, 113.9, 114.3 (2 C), 117.3, 118.9, 122.4, 123.6, 125.2, 125.7, 127.6 (2 C), 127.8 (2 C), 128.1, 128.2 (2 C), 128.6 (2 C), 130.4, 131.5, 131. 7 (2 C), 132.8, 137.1, 138. 7, 140.6, 154.6, 160.0, 160.6, 190.6 ppm. IR (mineral oil): 1766, 1660 cm−1. Anal. Calcd (%) for C31H21BrN2O5: C 65.67; H 4.18; N 4.19. Found: C 65.94; H 4.13; N 4.11. Crystal structure of compound 1 was deposited at the Cambridge Crystallographic Data Centre with the deposition number CCDC 2047333, CCDC Refcode = FADPUZ [6].

Supplementary Materials

The following supporting information can be downloaded online, copies of NMR spectra for new compound.

Author Contributions

Conceptualization, A.N.M.; methodology, E.E.K. and A.N.M.; validation, E.E.K. and A.N.M., investigation, E.E.K. (synthetic chemistry), M.V.D. (X-ray analysis); writing—original draft preparation, E.E.K.; writing—review and editing, E.E.K. and M.V.D.; visualization, E.E.K.; supervision, A.N.M.; project administration, A.N.M.; funding acquisition A.N.M. All authors have read and agreed to the published version of the manuscript.

Funding

This study was performed under financial support by the Perm Research and Educational Center “Rational subsoil use”.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The presented data are available in this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zhang, J.; Xu, W. Methods Of NAD+-Dependent Deacetylase Inhibitors. Patent WO2005053609A2, 16 June 2005. [Google Scholar]
  2. Sugumi, H.; Niijima, J.; Kotake, Y.; Okada, T.; Kamata, J.-I.; Yoshimatsu, K.; Nagasu, T.; Nakamura, K.; Uenaka, T.; Yamaguchi, A.; et al. Fused polycyclic heterocycle derivatives. Patent US5952335A, 14 September 1999. [Google Scholar]
  3. Kamata, J.; Okada, T.; Kotake, Y.; Niijima, J.; Nakamura, K.; Uenaka, T.; Yamaguchi, A.; Tsukahara, K.; Nagasu, T.; Koyanagi, N.; et al. Synthesis and Evaluation of Novel Pyrimido-Acridone, -Phenoxadine, and -Carbazole as Topoisomerase II Inhibitors. Chem. Pharm. Bull. 2004, 52, 1071–1081. [Google Scholar] [CrossRef] [PubMed]
  4. Lystsova, E.A.; Khramtsova, E.E.; Maslivets, A.N. Acyl(imidoyl)ketenes: Reactive Bidentate Oxa/Aza-Dienes for Organic Synthesis. Symmetry 2021, 13, 1509. [Google Scholar] [CrossRef]
  5. Aliev, Z.G.; Krasnykh, O.P.; Maslivets, A.N.; Andreichikov, Y.S.; Atovmyan, L.O. Chemistry of acyl(imidoyl)ketenes. 3. Synthesis and structure of l-p-bromophenyl-2-p-methoxyphenyl-4-p-toluoyl-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione. Russ. Chem. Bull. 1999, 48, 608–611. [Google Scholar] [CrossRef]
  6. Stepanova, E.E.; Dmitriev, M.V.; Maslivets, A.N. CCDC 2047333: Experimental Crystal Structure Determination; Cambridge Crystallographic Data Centre: Cambridge, UK, 2020. [Google Scholar] [CrossRef]
  7. Zampieri, D.; Mamolo, M.G.; Filingeri, J.; Fortuna, S.; De Logu, A.; Sanna, A.; Zanon, D. Design, synthesis and antimycobacterial activity of benzoxazinone derivatives and open-ring analogues: Preliminary data and computational analysis. Bioorg. Med. Chem. Lett. 2019, 29, 2468–2474. [Google Scholar] [CrossRef] [PubMed]
  8. Maslivets, A.N.; Mashevskaya, I.V.; Krasnykh, O.P.; Shurov, S.N.; Andreichikov, Y.S. 5-membered 2, 3-dioxoheterocycles. 33. synthesis of 3-aroyl-1, 2-dihydro-4H-pyrrolo-[5.1-C][1, 4] benzoxazine-1, 2, 4-triones and their interaction with water and alcohols. Zhurn. Org. Khim. 1992, 28, 2545–2553. [Google Scholar]
  9. CrysAlisPro, Oxford Diffraction/Agilent Technologies UK Ltd., Yarnton, England, Version 1.171.37.33 (Release 27-03-2014 CrysAlis171.NET). Available online: https://www.rigaku.com/products/crystallography/crysalis (accessed on 28 December 2022).
  10. Farrugia, L.J. WinGX and ORTEP for Windows: An update. J. Appl. Cryst. 2012, 45, 849–854. [Google Scholar] [CrossRef]
  11. Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A: Found. Crystallogr. 2008, 64, 112–122. [Google Scholar] [CrossRef] [PubMed]
  12. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Crystallogr. Sect. C: Struct. Chem. 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
  13. Sandhar, R.K.; Sharma, J.R.; Manrao, M.R. Synthesis and fungitoxicity of aldimines and 4-thiazolidinones derived from 4-bromoaniline. J. Indian Chem. Soc. 2008, 85, 220–223. [Google Scholar]
Figure 1. Potential pharmaceutical substances, bearing pyrimidino[4,3-c][1,4]benzoxazine core.
Figure 1. Potential pharmaceutical substances, bearing pyrimidino[4,3-c][1,4]benzoxazine core.
Molbank 2023 m1583 g001
Scheme 1. Synthesis of fused heterocycles A and B via reactions of acyl(imidoyl)ketenes C.
Scheme 1. Synthesis of fused heterocycles A and B via reactions of acyl(imidoyl)ketenes C.
Molbank 2023 m1583 sch001
Scheme 2. Synthesis of 4-benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione 1.
Scheme 2. Synthesis of 4-benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione 1.
Molbank 2023 m1583 sch002
Figure 2. Solid state fluorescence of compound 1.
Figure 2. Solid state fluorescence of compound 1.
Molbank 2023 m1583 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Khramtsova, E.E.; Dmitriev, M.V.; Maslivets, A.N. 4-Benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione. Molbank 2023, 2023, M1583. https://doi.org/10.3390/M1583

AMA Style

Khramtsova EE, Dmitriev MV, Maslivets AN. 4-Benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione. Molbank. 2023; 2023(1):M1583. https://doi.org/10.3390/M1583

Chicago/Turabian Style

Khramtsova, Ekaterina E., Maksim V. Dmitriev, and Andrey N. Maslivets. 2023. "4-Benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione" Molbank 2023, no. 1: M1583. https://doi.org/10.3390/M1583

APA Style

Khramtsova, E. E., Dmitriev, M. V., & Maslivets, A. N. (2023). 4-Benzoyl-2-(4-bromophenyl)-1-(4-methoxyphenyl)-1,2-dihydropyrimidino[4,3-c][1,4]benzoxazine-3,5-dione. Molbank, 2023(1), M1583. https://doi.org/10.3390/M1583

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop